Next questions in the management of retroperitoneal sarcoma.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
9
6
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
ppublish
Résumé
Retroperitoneal soft-tissue sarcomas (RPS) are a group of rare, histologically distinct tumours with variable recurrence patterns depending on histological type. This review will discuss the growing body of evidence supporting histology-specific, multidisciplinary management and highlight areas of future research for patients with RPS. Histology-tailored surgery is the cornerstone of management in patients with localized RPS. Further efforts to develop resectability criteria and identify patients who will benefit from neoadjuvant treatment strategies will help standardize the treatment of patients with localized RPS. Surgery for local recurrence is well tolerated in selected patients and re-iterative surgery in liposarcoma (LPS) may be beneficial at the time of local recurrence. The management of advanced RPS holds promise with several trials currently investigating systemic treatment beyond conventional chemotherapy. The management of RPS has made significant progress over the past decade owing to international collaboration. Ongoing efforts to identify patients who will derive the most benefit from all treatment strategies will continue to advance the field of RPS.
Identifiants
pubmed: 37222202
doi: 10.1097/CCO.0000000000000954
pii: 00001622-202307000-00012
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-308Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Blay J, Honoré C, Stoeckle E, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol 2019; 30:1143–1153.
de Pinieux G, Karanian M, Le Loarer F, et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One 2021; 16:e0246958.
Tan MC, Brennan M, Kuk D, et al. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. Ann Surg 2016; 263:593–600.
Gronchi A, Strauss D, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multiinstitutional collaborative RPS working group. Ann Surg 2016; 263:1002–1009.
van Houdt WJ, Zaidi S, Messiou C, et al. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol 2017; 29:260–267.
Anaya DA, Lahat G, Wang X, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol 2010; 21:397–402.
Ardoino I, Miceli R, Berselli M, et al. Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. Cancer 2010; 116:2429–2436.
Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106:dju124.
Fiore M, Ljevar S, Pasquali S, et al. Preoperative neutrophil-to-lymphocyte ratio and a new inflammatory biomarkers prognostic index for primary retroperitoneal sarcomas: retrospective monocentric study. Clin Cancer Res 2022; 29:614–620.
Callegaro D, Pasquali S, Miceli R, et al. Identification of a genomic signature that improves the performance of the sarculator nomogram for patients with primary retroperitoneal sarcoma. 2022. Presented at Connective Tissue Oncology Society Meeting.
Swallow CJ, Strauss DC, Bonvalot S, et al. Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol 2021; 28:7873–7888.
Bonvalot S, Raut CP, Pollock RE, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC–STBSG. Ann Surg Oncol 2012; 19:2981–2991.
D’Ambrosio L, Van Houdt W, Stelmes J, et al. First and further-line multidisciplinary treatment of retroperitoneal sarcomas. Curr Opin Oncol 2022; 34:328–334.
Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol 2010; 17:1507–1514.
Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol 2009; 27:24–30.
Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update. Expert Rev Anticancer Ther 2019; 19:613–631.
Ng D, Acidi B, Callegaro D, et al. Why do patients with nonmetastatic primary retroperitoneal sarcoma not undergo resection? A retrospective series of 276 patients treated in two specialized sarcoma centres. 2022. Presented at Connective Tissue Oncology Society Meeting.wsuioyuy65.
Restrepo Lopez J, Barretta F, Iadecola S, et al. Do early recurrent primary retroperitoneal sarcoma (RPS) have similar survival to inoperable RPS: was surgery worth it? 2022. Presented at Connective Tissue Oncology Society Meeting.
MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report From the Transatlantic RPS Working Group. Ann Surg 2018; 267:959–964.
Fiore M, Brunelli C, Miceli R, et al. A prospective observational study of multivisceral resection for retroperitoneal sarcoma: clinical and patient-reported outcomes 1 year after surgery. Ann Surg Oncol 2021; 28:3904–3916.
Zhuang A, Fang Y, Ma L, et al. Does aggressive surgery mean worse quality of life and functional capacity in retroperitoneal sarcoma patients? A retrospective study of 161 patients from China. Cancers 2022; 14:
Martins A, Bennister L, Fern LA, et al. Development of a patient-reported experience questionnaire for patients with sarcoma: the Sarcoma Assessment Measure (SAM). Qual Life Res 2020; 29:2287–2297.
Jakob J, Hentschel L, Richter S, et al. Transferability of health-related quality of life data of large observational studies to clinical practice: comparing retroperitoneal sarcoma patients from the PROSa Study to a TARPSWG cohort. Oncol Res Treat 2022; 45:660–669.
Bonvalot S, Gronchi A. Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020; 21:1366–1377.
Chowdhary M, Spraker MB. Preoperative radiotherapy for retroperitoneal sarcoma. Lancet Oncol 2021; 22:e2.
DeLaney T, Mullen JT, Wang D, et al. Preoperative radiotherapy for retroperitoneal sarcoma. Lancet Oncol 2021; 22:e1.
Callegaro D, Raut CP, Ajayi TT, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 Trial (STRASS) versus off-trial (STREXIT) results. Ann Surg 2022; [Epub ahead of print].
Haas RL, Walraven I, Lecointe-Artzner E, et al. Extrameningeal solitary fibrous tumors-surgery alone or surgery plus perioperative radiotherapy: a retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. Cancer 2020; 126:3002–3012.
Haas RL, Walraven I, Lecointe-Artzner E, et al. Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy? Acta Oncol 2021; 60:35–41.
Tseng WW, Barretta F, Conti LL, et al. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multiinstitutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Cancer 2021; 127:729.
Movva S, von Mehren M, Ross EA, et al. Patterns of chemotherapy administration in high-risk soft tissue sarcoma and impact on overall survival. J Natl Compr Canc Netw 2015; 13:1366–1374.
Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010; 46:72–83.
D’Ambrosio L, Touati N, Blay J, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer 2020; 126:2637–2647.
Pautier P, Italiano A, Piperno-Neumann S, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2022; 23:1044–1054.
Roland CL, Keung EZ, Lazar AJ, et al. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). JCO 2020; 38:11505.
Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41:2853–2860.
Gronchi A, Hindi N, Cruz J, et al. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. EClinicalMedicine 2019; 9:35–43.
Gronchi A, Hindi N, Blay J, et al. Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: an international, prospective, phase II trial in localized myxoid liposarcoma—a collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study. JCO 2020; 38:11514.
Gyorki DE, Brennan MF. Management of recurrent retroperitoneal sarcoma. J Surg Oncol 2014; 109:53–59.
Ikoma N, Torres KE, Lin HY, et al. Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. J Surg Oncol 2017; 116:313–319.
Raut CP, Callegaro D, Miceli R, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal rarcoma: a study and novel nomogram from TARPSWG. Clin Cancer Res 2019; 25:2664–2671.
Wang Z, Wu J, Li C, et al. Patients with first recurrent retroperitoneal sarcoma that can be macroscopically completely resected can achieve comparable outcomes with that of primary patients after en bloc resection of tumor and adjacent organs. Front Surg 2022; 9:956384.
Nessim C, Raut CP, Callegaro D, et al. Postoperative morbidity after resection of recurrent retroperitoneal sarcoma: a report from the Transatlantic Australasian RPS Working Group (TARPSWG). Ann Surg Oncol 2021; 28:2705–2714.
Tseng WW, Swallow CJ, Strauss DC, et al. Management of locally recurrent retroperitoneal sarcoma in the adult: an updated consensus approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Annals Surg Oncol 2022; 29:7335–7348.
van Houdt WJ, Fiore M, Barretta F, et al. Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: a study from TARPSWG. Cancer 2020; 126:4917–4925.
Demetri GD, Schöffski P, Grignani G, et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol 2017; 35:3433–3439.
Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387:1629–1637.
Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016; 34:786–793.
van der Graaf W, Blay TA, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879–1886.
Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18:1493–1501.
Ayodele O, Wang BX, Pfister TD, et al. A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS). JCO 2021; 39:11522.
Somaiah N, Conley AP, Parra ER, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 2022; 23:1156–1166.
Kasper B, D’Ambrosio L, Davis EJ, et al. What clinical trials are needed for treatment of leiomyosarcoma? Curr Treat Options Oncol 2022; 23:439–449.